14.25GBp-1.72%Mkt Cap: 17.50M GBpP/E: —Last update: 2026-05-13
Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies for cancer and infectious diseases in the United Kingdom, the rest of …
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Valuation
P/E (Trailing)—
P/E (Forward)-16.67
PEG—
P/B25.00
P/S11.75
EV/EBITDA-12.29
EV/Revenue10.77
EPS (TTM)-0.02
EPS (Forward)-0.01
Cash Flow & Leverage
FCF Yield-4.44%
FCF Margin-48.68%
Operating CF-1.36M GBp
CapEx (TTM)10.00K GBp
Net Debt/EBITDA-0.10
Net Debt136.00K GBp
Technical
SMA 5013.27 (+7.4%)
SMA 20014.23 (+0.1%)
Beta1.20
S&P 52W Chg24.23%
Avg Vol (30d)586.92K
Avg Vol (10d)780.63K
Technical Indicators
RSI (14)54.1
MACD0.1433
MACD Signal0.0926
MACD Hist.+0.0507
BB Upper15.28 GBp
BB Middle13.87 GBp
BB Lower12.46 GBp
BB Width20.31%
ATR (14)1.558 GBp
Vol Ratio (20d)0.64x
52W Range
5.80056% of range21.00
52W High21.00 GBp
52W Low5.800 GBp
Profitability
Gross Margin21.88%
EBITDA Margin-87.59%
Profit Margin-87.18%
Oper. Margin-64.44%
ROE-256.05%
ROA-129.48%
Revenue Growth-30.60%
Earnings Growth—
Balance Sheet
Debt/Equity0.03
Current Ratio1.80
Quick Ratio1.45
Book Value/Sh0.0060 GBp
Cash/Share0.0020 GBp
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 GBp
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Ownership
Shares Out.125.02M
Float102.82M
Insiders11.59%
Institutions27.51%
Analyst Consensus
Rating0.0 (Hold)
Target (Mean)—
Target Range—
# Analysts—
Company
Market Cap17.50M GBp
Enterprise Value17.18M GBp
Revenue (TTM)1.60M GBp
Gross Profit430.00K GBp
Net Income (TTM)-1.71M GBp
Revenue/Share0.0150 GBp
Fiscal Year EndMar 2025
MR QuarterSep 2025
Employees24
Last Price14.25 GBp
CountryGB
SectorHealthcare
IndustryBiotechnology
ISIN—